Orio Therapeutics

Orio Therapeutics originates from the research work of its two co-founders in the field of regenerative medicine and protein engineering. The company is based on a patented technology they developed at Monash University, Australia, allowing them to integrate a "built-in" delivery system for any therapeutic protein. Based on the Swiss roots of the co-founders and the Australian origin of the technology, Orio Therapeutics is seizing this opportunity to develop its activities in Monthey and Melbourne.  Orio Therapeutics as set as a priority for first product the development of a cardioprotective drug for heart attack patients (STEMI). The company is now seeking seed funding.